OBJECTIVE: To determine if lymphopenia is associated with clinical/immunologic manifestations, disease activity, and disease damage in systemic lupus erythematosus (SLE). METHODS: The study group comprised 591 patients with SLE participating in a multiethnic, longitudinal outcome study. Cumulative clinical/immunologic (per American College of Rheumatology criteria) and pharmacologic treatment variables were obtained at enrollment (T0) and last visit (TL). Lymphopenia (<1,500/mm3) was scored only when clinically attributable to SLE and not to medications or other causes. Lymphocyte counts were expressed in 4 categories per the Systemic Lupus Activity Measure (SLAM): normal (> or =1,500/mm3), mild (1,000-1,499/mm3), moderate (500-999/mm3), and marked (<500/mm3). Disease activity was assessed with the SLAM and the Physician's Global Assessment (PGA). Disease damage was determined with the Systemic Lupus International Collaborating Clinics Damage Index (SLICC-DI). The relationship of lymphopenia with cumulative clinical/immunologic and pharmacologic treatment variables was first examined, then the association between the SLAM, PGA, and SLICC-DI scores with different categories of lymphopenia was examined by generalized estimating equation (GEE) regression analyses. Ethnicity, age, and sex were entered into all regression models. RESULTS: At T0 and TL, lymphopenia was found to be positively associated with renal involvement, leukopenia, anti-double-stranded DNA antibodies, anti-Ro antibodies, and the use of glucocorticoids, azathioprine, and methotrexate, but was negatively associated with photosensitivity. On GEE analyses, marked lymphopenia at T0 and moderate and marked lymphopenia for all visits were independently associated with higher SLAM, PGA, and SLICC-DI scores. CONCLUSION: Lymphopenia is associated with several clinical/immunologic manifestations in SLE. Moderate and marked lymphopenia are associated with higher disease activity and damage accrual.
OBJECTIVE: To determine if lymphopenia is associated with clinical/immunologic manifestations, disease activity, and disease damage in systemic lupus erythematosus (SLE). METHODS: The study group comprised 591 patients with SLE participating in a multiethnic, longitudinal outcome study. Cumulative clinical/immunologic (per American College of Rheumatology criteria) and pharmacologic treatment variables were obtained at enrollment (T0) and last visit (TL). Lymphopenia (<1,500/mm3) was scored only when clinically attributable to SLE and not to medications or other causes. Lymphocyte counts were expressed in 4 categories per the Systemic Lupus Activity Measure (SLAM): normal (> or =1,500/mm3), mild (1,000-1,499/mm3), moderate (500-999/mm3), and marked (<500/mm3). Disease activity was assessed with the SLAM and the Physician's Global Assessment (PGA). Disease damage was determined with the Systemic Lupus International Collaborating Clinics Damage Index (SLICC-DI). The relationship of lymphopenia with cumulative clinical/immunologic and pharmacologic treatment variables was first examined, then the association between the SLAM, PGA, and SLICC-DI scores with different categories of lymphopenia was examined by generalized estimating equation (GEE) regression analyses. Ethnicity, age, and sex were entered into all regression models. RESULTS: At T0 and TL, lymphopenia was found to be positively associated with renal involvement, leukopenia, anti-double-stranded DNA antibodies, anti-Ro antibodies, and the use of glucocorticoids, azathioprine, and methotrexate, but was negatively associated with photosensitivity. On GEE analyses, marked lymphopenia at T0 and moderate and marked lymphopenia for all visits were independently associated with higher SLAM, PGA, and SLICC-DI scores. CONCLUSION:Lymphopenia is associated with several clinical/immunologic manifestations in SLE. Moderate and marked lymphopenia are associated with higher disease activity and damage accrual.
Authors: Danieli Andrade; Patricia B Redecha; Milena Vukelic; Xiaoping Qing; Giorgio Perino; Jane E Salmon; Gloria C Koo Journal: Arthritis Rheum Date: 2011-09
Authors: D Mesquita; G Mastroianni Kirsztajn; M F Franco; L A Reis; S F Perazzio; F V Mesquita; V da Silva Ferreira; L E Coelho Andrade; A W Silva de Souza Journal: Clin Exp Immunol Date: 2017-10-10 Impact factor: 4.330
Authors: Jasmine R Gaddy; Evan S Vista; Julie M Robertson; Amy B Dedeke; Virginia C Roberts; Wendy S Klein; Jeremy H Levin; Fabio H Mota; Tina M Cooper; Gloria A Grim; Sohail Khan; Judith A James Journal: J Rheumatol Date: 2012-08-15 Impact factor: 4.666
Authors: Andreas Holbro; Philipp Schuetz; Christoph Berger; Christoph Hess; Thomas Daikeler Journal: Rheumatol Int Date: 2008-11-08 Impact factor: 2.631
Authors: B Namjou; C Gray-McGuire; A L Sestak; G S Gilkeson; C O Jacob; J T Merrill; J A James; E K Wakeland; Q-Z Li; C D Langefeld; J Divers; J Ziegler; K L Moser; J A Kelly; K M Kaufman; J B Harley Journal: Genes Immun Date: 2009-05-14 Impact factor: 2.676
Authors: Kenichiro Maeda; Alex Malykhin; Brittany N Teague-Weber; Xiao-Hong Sun; A Darise Farris; K Mark Coggeshall Journal: Blood Date: 2009-02-17 Impact factor: 22.113